Halol plant remediation uncertainty
Halol plant remains under FDA scrutiny; no timeline for re-inspection or resolution, impacting US generic supply.
SUNPHARMA / Q2-FY24 / risks
Keep the risk register visible.
Sunpharma · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Taro Israel operations exposure
Taro's operations in Israel may be impacted by regional conflict, though management says business continuity is maintained.
US generic pricing pressure
Management sees no significant improvement in generic pricing environment; pricing remains product-specific and competitive.